Leerink Partnrs Has Pessimistic View of RCKT FY2026 Earnings

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT - Free Report) - Equities researchers at Leerink Partnrs decreased their FY2026 EPS estimates for Rocket Pharmaceuticals in a research report issued to clients and investors on Wednesday, October 15th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings per share of ($1.67) for the year, down from their prior estimate of ($1.66). The consensus estimate for Rocket Pharmaceuticals' current full-year earnings is ($2.83) per share.

Rocket Pharmaceuticals (NASDAQ:RCKT - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.02). During the same quarter last year, the firm earned ($0.74) EPS.

A number of other equities research analysts also recently weighed in on the stock. Bank of America raised shares of Rocket Pharmaceuticals from a "neutral" rating to a "buy" rating and raised their target price for the company from $4.00 to $10.00 in a research note on Wednesday, August 20th. Cantor Fitzgerald lowered their target price on shares of Rocket Pharmaceuticals from $10.00 to $8.00 and set an "overweight" rating on the stock in a research note on Friday, August 8th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Rocket Pharmaceuticals in a research note on Wednesday, October 8th. Leerink Partners lowered their target price on shares of Rocket Pharmaceuticals from $9.00 to $7.00 and set a "market perform" rating on the stock in a research note on Friday, October 3rd. Finally, Chardan Capital reissued a "buy" rating and set a $11.00 price target on shares of Rocket Pharmaceuticals in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $16.67.

Rocket Pharmaceuticals Trading Down 5.7%

Shares of RCKT opened at $4.00 on Friday. The firm's 50 day simple moving average is $3.30 and its 200 day simple moving average is $4.07. The company has a market capitalization of $431.60 million, a P/E ratio of -1.59 and a beta of 0.60. The company has a debt-to-equity ratio of 0.05, a current ratio of 6.39 and a quick ratio of 6.39. Rocket Pharmaceuticals has a 1-year low of $2.19 and a 1-year high of $18.89.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in RCKT. Rhumbline Advisers increased its stake in shares of Rocket Pharmaceuticals by 8.4% in the first quarter. Rhumbline Advisers now owns 107,638 shares of the biotechnology company's stock worth $718,000 after buying an additional 8,299 shares during the period. SG Americas Securities LLC increased its stake in shares of Rocket Pharmaceuticals by 112.3% in the first quarter. SG Americas Securities LLC now owns 116,571 shares of the biotechnology company's stock worth $778,000 after buying an additional 61,650 shares during the period. PFG Investments LLC purchased a new position in shares of Rocket Pharmaceuticals in the first quarter worth $89,000. Sovran Advisors LLC increased its stake in shares of Rocket Pharmaceuticals by 114.3% in the first quarter. Sovran Advisors LLC now owns 323,091 shares of the biotechnology company's stock worth $2,045,000 after buying an additional 172,324 shares during the period. Finally, Bank of New York Mellon Corp increased its stake in shares of Rocket Pharmaceuticals by 8.1% in the first quarter. Bank of New York Mellon Corp now owns 209,967 shares of the biotechnology company's stock worth $1,400,000 after buying an additional 15,785 shares during the period. 98.39% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Rocket Pharmaceuticals

In other Rocket Pharmaceuticals news, insider John Militello sold 28,918 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Tuesday, October 14th. The shares were sold at an average price of $3.96, for a total transaction of $114,515.28. Following the transaction, the insider directly owned 67,006 shares of the company's stock, valued at approximately $265,343.76. This trade represents a 30.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Jonathan David Schwartz sold 11,161 shares of Rocket Pharmaceuticals stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $3.02, for a total transaction of $33,706.22. Following the transaction, the insider directly owned 224,094 shares in the company, valued at $676,763.88. This trade represents a 4.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 64,368 shares of company stock valued at $221,675. 24.76% of the stock is owned by insiders.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.